Somatostatin inhibition of insulin secretion in insulin-producing tumors

Scuro, L.A.; Cascio, Vincenzo Lo; Adami, Silvano; Galvanini, G.; Bianchi, Ivo; Cominacini, Luciano; Corgnati, A.

doi:10.1016/0026-0495(76)90056-1

Cited by 22 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Entopic endocrine tumors include insulinomas, glucagonomas, somatostatinomas, and pancreatic polypeptide (PP) islet cell tumors (PPomas, PP apudomas) ( 154). Clinical studies have demonstrated that infusion of somatostatin inhibited the secretion of insulin in patients with insulinomas and of glucagon in a case of glucagonoma ( 162,163,(4)(5)(6). Among the chief ectopic endocrine tumors of the pancreas are gastrinomas associated with Zollinger-Ellison syndrome and vasoactive intestinal polypeptide (VIP)-producing tumors (VIPomas) which result in Verner-Morrison watery diarrhea syndrome.…”

Section: Chondrosarcomas and Osteosarcomas Or Tumors Of Cartilage Andmentioning

confidence: 99%

Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Schally¹,

Comaru‐Schally²,

Redding³

1984

Experimental Biology and Medicine

132

106

View full text Add to dashboard Cite

Section: Chondrosarcomas and Osteosarcomas Or Tumors Of Cartilage Andmentioning

confidence: 99%

Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Schally¹,

Comaru‐Schally²,

Redding³

1984

Experimental Biology and Medicine

132

106

View full text Add to dashboard Cite

“…We retrospectively studied patients with insulinoma in comparison to patients with NIPHS and patients with excluded hypoglycemic disorder. We developed normative criteria from combined OGTT-fasting tests and available somatostatin infusion tests [20][21][22] in representative groups of patients with and without insulinoma. In patients with insulinoma we identified three different insulin secretion patterns: the autonomous, the inadequate suppression, and the late-burst type pattern.…”

Section: Introductionmentioning

confidence: 99%

Differentiation of Insulin Secretion Patterns in Insulinoma

2008

View full text Add to dashboard Cite

Background In patients with insulinoma, biochemical proof of inappropriately elevated insulin secretion during hypoglycemia is required prior to surgery. Because circulating insulin levels usually vary widely, we have used the combined OGTT-fasting test to define new normative criteria for a retrospective systematic analysis. Methods We retrospectively analyzed insulin concentrations from OGTT-fasting tests of 64 patients with surgically removed insulinomas. In addition, the response to intravenous somatostatin infusions was estimated. Normative criteria were defined to obtain comparable estimates of insulin concentrations: basal, glucose-stimulated maximum, postglucose plateau, and secretory bursts. Results Three types of insulin secretion patterns were identified: (1) the autonomous secretion pattern (type 1, N = 17) with basal and post-OGTT plateau insulin concentrations of approximately 50 mU/L, suppression after OGTT by 41%, virtual absence of distinctive secretory bursts, and resistance to somatostatin-mediated suppression (25 %); (2) the inadequate suppression pattern (type 2, N = 28) with moderately elevated basal and post-OGTT insulin concentrations of approximately 20 mU/L, suppression after OGTT by 73%, absence of secretory bursts, and incomplete somatostatin-induced suppression (56 %); (3) the late-burst secretion pattern (type 3, N = 19) with similar basal and post-OGTT insulin concentrations of 17 mU/L, suppression after OGTT by 76%, true insulin bursts of D 13 ± 11 mU/L (184%), and nearly complete somatostatininduced suppression by 64%. Conclusions By means of a new normative analysis of the combined OGTT-fasting test, three different patterns of insulin secretion can be described in patients with insulinoma: the autonomous secretion type, the inadequate suppression type, and the late-burst secretion type.

show abstract

“…These actions include inhibition of the release of insulin and glucagon and suppression of the secretion or action (or both) of gastrin, secretin, and CCK (11)(12)(13)(14). Clinical studies have demonstrated that somatostatin or its analogs inhibit insulin secretion in patients with insulinomas and glucagon release in cases of glucagonomas (11,15,16). The secretions of ectopic endocrine tumors of the pancreas, including gastrin secreted from gastrinomas and vasoactive intestinal peptide (VIP) released from vipomas, are also suppressed by somatostatin or its analogs (17,18).…”

mentioning

confidence: 99%

“…Somatostatin inhibits not only the liberation of insulin and glucagon but also the release or action (or both) of secretin, gastrin, CCK, and other gastrointestinal peptides such as VIP and motilin (11)(12)(13)(14)(15)(16)(17)(18). Somatostatin has been shown to suppress exocrine pancreatic secretion in rats, dogs and humans (11,12,14,18 (34) and found that testosterone levels were significantly reduced in patients with pancreatic carcinoma when compared to controls, possibly due to the uptake and metabolism within the tumor (34,35).…”

mentioning

confidence: 99%

Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.

Redding¹,

Schally²

1984

Proc. Natl. Acad. Sci. U.S.A.

141

View full text Add to dashboard Cite

953Retraction. We now observe alterations in a number of the properties of arl mutants of Escherichia coli; some of these properties were originally described by us in a paper entitled "DNA from recombinogenic bacteriophages generated by arn mutants of Escherichia coli is cleaved by single-strandspecific endonuclease Si", John B. Hays and Brent E. Korba, which appeared in number 12, December 1979, of Proc. Natl. Acad. Sci. USA (76,(6066)(6067)(6068)(6069)(6070). With respect to these latter phenomena, we now find that X phages grown on arl bacteria ("Arl-phages") recombine only 1.2-1.5 rather than 3-5 times as much as "Arl+" phages in subsequent onestep-growth infections, and DNA from Arl-phages no longer appears sensitive to the single-strand-specific S1 nuclease. Some arl phenomena described elsewhere-e.g., decreased resistance to EcoRII restriction by arl phages and enhanced recombination of Arl-plasmids-remain approximately unchanged. The phage-growth properties of both wild-type and arl bacteria using our standard phage growth medium are greatly altered from those described previously, and some genetic properties of the mutants appear changed. It remains to be determined to what extent alterations in arl properties are due to changes in growth medium and/or genetic instability. Fuller accounts of the present status of arl phenomena appear elsewhere (Hays, J. B. & Korba, B. E., J. Mol. Biol. and Cell, in press).Correction. In the article "Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones" by

show abstract

Somatostatin inhibition of insulin secretion in insulin-producing tumors

Cited by 22 publications

References 16 publications

Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Differentiation of Insulin Secretion Patterns in Insulinoma

Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.

Contact Info

Product

Resources

About